Does the DESyne novolimus-eluting coronary stent reduce device- and patient-oriented events compared to the Endeavor zotarolimus-eluting coronary stent?
The DESyne novolimus-eluting stent demonstrated significantly lower device- and patient-oriented events compared to the Endeavor zotarolimus-eluting stent at 5 years, though larger studies are needed to confirm clinical outcomes.
At five-year follow-up, the incidence of device- and patient-oriented events was significantly lower in the NES group. Further studies, adequately powered for clinical outcomes, are warranted.
Iqbal et al. (2016) studied this question.